In a therapeutic landscape defined by innovation, few areas are evolving as quickly as the treatment of hemophilia. With that rapid pace comes an urgent need for education that doesn’t just keep up, but leads; that’s the driving force behind “Updates in FVIIIa Mimetics: Advancing Hemophilia Treatment Today and Tomorrow.” The globally oriented education initiative was developed by The France Foundation (TFF) in collaboration with the International Society on Thrombosis and Haemostasis (ISTH) and is supported by Novo Nordisk and Roche. 

From the ISTH Congress symposium to an online module and a host of supplementary learning tools, this initiative is all about current and emerging FVIIIa mimetics, and is designed to help prepare hematology care teams to make more informed, personalized decisions in patient care. 

A Spotlight on Mechanisms, Molecules, and Momentum 

The FDA-approved FVIIIa mimetic emicizumab redefined hemophilia treatment by offering subcutaneous administration and utility for patients with factor inhibitors. Now, a second generation of mimetics like Mim8, NXT007, and Inno8 are poised to extend that transformation even further, with improvements in potency, dosing frequency, and administration methods. 

This education was created to highlight the difference between these molecules and their mechanisms of action. It also guides clinicians through early clinical data and explains how to apply those findings to real-world patient care. By the end of this program, learners will not only understand the differences between approved and investigational agents, but they'll also be able to explain how FVIIIa mimetics function biologically and therapeutically. 

Built around a blended model of live, digital, and on-demand learning, the program was designed to accommodate the realities of busy clinicians. Here’s how we’re reaching them: 

ISTH 2025 Symposium 

Held at the ISTH Congress in Washington, DC, this live event brought together international faculty experts to explore the biology, efficacy, and future of FVIIIa mimetics in hemophilia A. Key agenda highlights included: 

• A comparative look at currently approved and investigational mimetics
• Custom-developed animated visuals explaining mechanisms of action
• Interactive panel discussions grounded in emerging clinical data 

ENABLE™ Online Module 

This self-paced module delivers the same core content in a case-based, interactive format that’s accessible anytime, anywhere. It enables: 

• Modular learning based on clinical themes
• Confidence-based assessments and interactive questions
• Built-in reinforcement 30 days after completion 

Supplementary Program Materials 

Downloadable slides, a companion animated video, and other digital tools further extend the reach, supporting education that’s not just informative, but transformative. 

This initiative reflects what can be accomplished when clinical need, strategic collaboration, and educational design converge. We thank Novo Nordisk and Roche, for their generous support of this initiative, and ISTH for its trusted partnership in bringing this program to the international hematology community. 

The field of hemophilia care is dynamic, data-rich, and full of clinical nuance; education like this ensures this data translates to patient benefits. If your organization is committed to transforming care through strategic, evidence-driven education, contact us using the form below.